智通财经APP获悉，艾美疫苗(06660)高开逾8%，截至发稿，涨8.32%，报5.99港元，成交额66.61万港元。
消息面上，艾美疫苗发布公告，集团按照既定公司战略积极推进疫苗产品管线的开发，利用mRNA技术平台优势，通过持续的技术创新，快速推进mRNA疫苗系列产品的研发，mRNA RSV(呼吸道合胞病毒)疫苗已于近日向美国食品和药品监督管理局(FDA)申报临床。
临床前动物试验中，第三方检测单位的检测结果显示：集团mRNA RSV疫苗特异性IgG抗体滴度、真病毒中和抗体效价、特异性T细胞免疫，均显著高于国际上市的mRNA RSV对照疫苗。
目前，全球尚无获批的针对RSV可用于临床的抗病毒特效药，接种疫苗进行主动免疫预防是避免RSV重症感染的有效手段。中国尚无RSV疫苗获批上市，2023年度RSV疫苗的全球销售额为24.6亿美元，根据行业顾问灼识咨询预测，预计到2030年，RSV疫苗在全球的市场规模将达到约167亿美元。该产品如进展顺利，将加快集团的国际化步伐，并给集团带来可观的业绩增长。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.